November 20, 2025
The Changing Nature of CGM
Yesterday Dexcom announced they have received FDA approval for their Smart Basal application. Per the company issued press release-
“DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
